New FDA Clarification Allows Wholesale by 503B Facilities to 503A Pharmacies | by: Sumeet Singh, Founder & Chairman | Article Posted: July 5, 2023 | New FDA Statement Overview The recent clarification from the U.S. Food and Drug Administration (FDA) regarding the...
Manufacturers Don’t Forget: Virginia Drug Pricing Reports are Due April 1st Written-by: Deneen Fumich, RPh March 2021, Virginia passed the...
Do Drug Price Transparency Laws Need to Explicitly Define Reporting Entities? Written-by: Deneen Fumich, RPh With the wave of 2021 passed Drug Price...
Importance of Current Good Manufacturing Practices (cGMP) Written-by: Deneen Fumich, RPh Did you know that a common cause of failing FDA inspections...
NABP Drug Distributor Accreditation Supply Chain Inspection Overview Written-by: Deneen Fumich, RPh Effective January 1, 2022, NABP made major...
FDA and NABP Temporarily Curtailing Onsite Inspections Due to COVID-19 In order to ensure the safety of its employees both FDA and the National...
Emergency Use Authorization Policy Ending for EAU Medical Devices Written-by: Sumeet Singh, CEO FDA To Host Webinar to Establish Transition...
